Encorafenib
- Generic Name
- Encorafenib
- Brand Names
- Braftovi
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27ClFN7O4S
- CAS Number
- 1269440-17-6
- Unique Ingredient Identifier
- 8L7891MRB6
- Background
Encorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most fr...
- Indication
Encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation and metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. It is also indicated in combination with cetuximab for the treatment of adult patients with metastatic colorecta...
- Associated Conditions
- Metastatic Colorectal Cancer (CRC), Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Unresectable Melanoma
- Associated Therapies
- -
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 3
- Registration Number
- NCT04801966
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
PF-07284892 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT04800822
- Locations
- 🇺🇸
Brigitte Harris Cancer Pavilion, Detroit, Michigan, United States
🇺🇸Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 78
- Registration Number
- NCT04720768
- Locations
- 🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺Box Hill Hospital, Box Hill, Victoria, Australia
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
- Conditions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Pierre Fabre Pharma GmbH
- Target Recruit Count
- 500
- Registration Number
- NCT04673955
- Locations
- 🇩🇪
Prctice, Naunhof, Sachsen, Germany
🇩🇪Private Practice, Würzburg, Germany
🇩🇪Clinic, Berlin, Germany
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 258
- Registration Number
- NCT04657991
- Locations
- 🇩🇪
HELIOS Klinikum Erfurt, Erfurt, Germany
🇺🇸UCLA - Hematology/Oncology - Administrative Office, Los Angeles, California, United States
🇺🇸Ronald Reagan UCLA Medical Center Drug Information Center , Dept. of Pharmaceutical Services (Drug, Los Angeles, California, United States
Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma
- Conditions
- Interventions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Jason J. Luke, MD
- Target Recruit Count
- 2
- Registration Number
- NCT04655157
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 816
- Registration Number
- NCT04607421
- Locations
- 🇺🇸
LAC & USC Medical Center, Los Angeles, California, United States
🇺🇸Cedars- Sinai Medical Center, Los Angeles, California, United States
🇺🇸Investigational Drug Service, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT04585815
- Locations
- 🇨🇳
Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 112
- Registration Number
- NCT04511013
- Locations
- 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸Grant Medical Center, Columbus, Ohio, United States
🇺🇸Mount Carmel Health Center West, Columbus, Ohio, United States
Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 6
- Registration Number
- NCT04390243
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Mayo Clinic in Arizona, Phoenix, Arizona, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.